Seelos Therapeutics Stock Working Capital
Seelos Therapeutics fundamentals help investors to digest information that contributes to Seelos Therapeutics' financial success or failures. It also enables traders to predict the movement of Seelos OTC Stock. The fundamental analysis module provides a way to measure Seelos Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Seelos Therapeutics otc stock.
Seelos |
Seelos Therapeutics OTC Stock Working Capital Analysis
Seelos Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Seelos Therapeutics Working Capital | (33.52 M) |
Most of Seelos Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Seelos Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionBased on the company's disclosures, Seelos Therapeutics has a Working Capital of (33.52 Million). This is 107.88% lower than that of the Pharmaceuticals sector and 106.22% lower than that of the Health Care industry. The working capital for all United States stocks is 102.27% higher than that of the company.
Seelos Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Seelos Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Seelos Therapeutics could also be used in its relative valuation, which is a method of valuing Seelos Therapeutics by comparing valuation metrics of similar companies.Seelos Therapeutics is currently under evaluation in working capital category among its peers.
Seelos Fundamentals
| Return On Equity | -5.84 | |||
| Return On Asset | -2.61 | |||
| Profit Margin | 2.03 % | |||
| Operating Margin | (8.35) % | |||
| Current Valuation | 10.45 M | |||
| Shares Outstanding | 581 K | |||
| Shares Owned By Insiders | 0.49 % | |||
| Shares Owned By Institutions | 4.46 % | |||
| Number Of Shares Shorted | 170.89 K | |||
| Price To Book | 15.10 X | |||
| Price To Sales | 0.37 X | |||
| Revenue | 2.2 M | |||
| Gross Profit | (46.65 M) | |||
| EBITDA | (40.44 M) | |||
| Net Income | (37.88 M) | |||
| Cash And Equivalents | 41.25 M | |||
| Cash Per Share | 0.39 X | |||
| Total Debt | 14.23 M | |||
| Debt To Equity | 0.73 % | |||
| Current Ratio | 3.60 X | |||
| Book Value Per Share | (135.50) X | |||
| Cash Flow From Operations | (23.91 M) | |||
| Short Ratio | 0.14 X | |||
| Earnings Per Share | 351.04 X | |||
| Target Price | 120.0 | |||
| Beta | 1.85 | |||
| Market Capitalization | 743.68 K | |||
| Total Asset | 5.42 M | |||
| Retained Earnings | (252.63 M) | |||
| Working Capital | (33.52 M) | |||
| Net Asset | 5.42 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in income. Note that the Seelos Therapeutics information on this page should be used as a complementary analysis to other Seelos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Seelos OTC Stock
If you are still planning to invest in Seelos Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Seelos Therapeutics' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |